Joinn Laboratories (China) Co (SHSE:603127) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603127 Joinn Laboratories (China) Co Ltd SHSE:603127
71 GF Score
Price ¥48.29
GF Value ¥17.62
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Joinn Laboratories (China) Co FFO per Share?

FFO per Share only applies to REITs.

SHSE:603127
71GF Score
Joinn Laboratories (China) Co Ltd SHSE:603127
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?

Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued. The current stock price of ¥48.29 is trading 174.1% above its estimated GF Value™ of ¥17.62. GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.

Key valuation signals for SHSE:603127:

  • FFO per Share:
  • GF Value™: ¥17.62 vs. price of ¥48.29 (174.1% above fair value)
  • GF Score™: 71/100 with 7 warning signs

No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Joinn Laboratories (China) Co Business Description

Other Exchanges 06127:Hong Kong
Address A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
71GF Score

Get the complete analysis for SHSE:603127

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥48.29
Price
¥17.62
GF Value